USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medrx Co., Ltd.

USPTO PatentsView assignee record - 28 granted patents across 8 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

15.0

Avg claims per patent

+150%

5-year grant velocity

The verdict

According to USPTO PatentsView, Medrx ranks #11,002 of 50,000 tracked US assignees by granted-patent volume, with 28 patents across 8 technology areas.

#11,002
of 50,000 US assignees by volume: Top 47%
by Innovation Score (36.1/100): 15.0
avg claims per patent: +150%
grant velocity, last 5 yrs

Portfolio overview

Medrx Co., Ltd. has been granted 28 US utility patents between 2015 and 2024, placing Medrx Co., Ltd. at #11,002 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 8 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.0 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Medrx Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Medrx sits between Manitou BF (28 patents, rank #10,991) and Mizkan Holdings Co., Ltd. (28 patents, rank #10,999) - the closest US assignees by grant volume. The composite Innovation Score of 36.1/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 20 grants, compared with 8 in the 2015–2019 window, a +150% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Medrx Co., Ltd.'s 15.0 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 8 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Manitou BF

28
Matrixed Reality…

28
Maxcyte

28
Mckinsey &

28
MHI Vestas Offsho…

28
Microbial Chemist…

28
Mineral Earth Sci…

28
Mizkan Holdings

28
Medrx ◀

28

What this shows Medrx holds 28 patents at rank #10,995, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medrx

By rank, the assignees closest to #10,995 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Medrx's primary technology class.

Medrx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Medrx Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	3.6%
2017	2	7.1%
2018	5	17.9%
2020	5	17.9%
2021	6	21.4%
2022	4	14.3%
2023	3	10.7%
2024	2	7.1%

Which technologies does Medrx Co., Ltd. patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 22

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 12

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 8

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 4

B32B - LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM 2

F04C - ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS ; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS 1

B08B - CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL 1

H04R - LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS 1

Top 8 of 8 technology areas

Grant record at a glance

Portfolio Volume 28 grants

CPC subclasses 8

Avg. claims / grant 15.0

Velocity +150%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#11,002

of 50,000 tracked assignees

Innovation Score

36.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Medrx Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medrx Co., Ltd. ranks #11,002 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medrx Co., Ltd. hold?

Medrx Co., Ltd. holds 28 US utility patents granted between 2015 and 2024, spanning 8 technology areas.

What is Medrx Co., Ltd.'s Innovation Score?

Medrx Co., Ltd. has an Innovation Score of 36.1 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medrx Co., Ltd. focus on?

Medrx Co., Ltd.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 22 patents. Grants appear in 8 CPC subclasses total.

Is Medrx Co., Ltd.'s patent grant rate increasing or decreasing?

Medrx Co., Ltd.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Medrx Co., Ltd.'s patents?

Medrx Co., Ltd.'s patents average 15.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Medrx Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Medrx's 28 grants land it in the top 47% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Medrx ranks #11,002 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.